scholarly journals Genetic Study of PHACTR1 and Fibromuscular Dysplasia, Meta-Analysis and Effects on Clinical Features of Patients

Hypertension ◽  
2020 ◽  
Vol 76 (1) ◽  
Author(s):  
Ewa Warchol-Celinska ◽  
Takiy Berrandou ◽  
Aleksander Prejbisz ◽  
Adrien Georges ◽  
Delia Dupré ◽  
...  
Keyword(s):  
Clinical Features ◽  
Genetic Study ◽  
Fibromuscular Dysplasia ◽  
Meta Analysis

scholarly journals GENETIC STUDY OF PHACTR1 AND FIBROMUSCULAR DYSPLASIA, META-ANALYSIS AND EFFECTS ON CLINICAL FEATURES OF PATIENTS

2019 ◽  
Vol 37 ◽  
pp. e88
Author(s):  
E. Warchol-Celinska ◽  
T. Berrandou ◽  
A. Prejbisz ◽  
A. Georges ◽  
D. Dupré ◽  
...  
Keyword(s):  
Clinical Features ◽  
Genetic Study ◽  
Fibromuscular Dysplasia ◽  
Meta Analysis

Cervical Spine Aneurysmal Bone Cysts: A Meta-Analysis of 114 Cases and Comparison of Clinical Features between Pediatric and Adult Patients

2017 ◽  
Vol 1 (1) ◽  
pp. 21-29
Author(s):  
Matthew Protas ◽  
Henry Wingfield ◽  
Basem Ishak ◽  
Rong Li ◽  
Rod J. Oskouian ◽  
...  
Keyword(s):  
Cervical Spine ◽  
Clinical Features ◽  
Meta Analysis ◽  
Adult Patients ◽  
Bone Cysts ◽  
Aneurysmal Bone Cysts

The association of SOX2 with clinical features and prognosis in colorectal cancer: A meta-analysis

2020 ◽  
Vol 216 (1) ◽  
pp. 152769 ◽  
Author(s):  
Xian-hui Zhang ◽  
Wei Wang ◽  
Ya-qi Wang ◽  
Lei Zhu ◽  
Lan Ma
Keyword(s):  
Colorectal Cancer ◽  
Clinical Features ◽  
Meta Analysis

scholarly journals Clinical features and outcomes of pregnant women with COVID-19: a systematic review and meta-analysis

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Yi-jie Gao ◽  
Lei Ye ◽  
Jia-shuo Zhang ◽  
Yang-xue Yin ◽  
Min Liu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pregnant Women ◽  
Clinical Features ◽  
Meta Analysis

scholarly journals Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sunny Singhal ◽  
Pramod Kumar ◽  
Sumitabh Singh ◽  
Srishti Saha ◽  
Aparajit Ballav Dey
Keyword(s):  
Systematic Review ◽  
Older Adults ◽  
Critically Ill ◽  
Clinical Features ◽  
Older Patients ◽  
Clinical Characteristics ◽  
Meta Analysis ◽  
Severe Infection ◽  
Factors Affecting ◽  
Pooled Prevalence

Abstract Background Few studies have focused on exploring the clinical characteristics and outcomes of COVID-19 in older patients. We conducted this systematic review and meta-analysis to have a better understanding of the clinical characteristics of older COVID-19 patients. Methods A systematic search of PubMed and Scopus was performed from December 2019 to May 3rd, 2020. Observational studies including older adults (age ≥ 60 years) with COVID-19 infection and reporting clinical characteristics or outcome were included. Primary outcome was assessing weighted pooled prevalence (WPP) of severity and outcomes. Secondary outcomes were clinical features including comorbidities and need of respiratory support. Result Forty-six studies with 13,624 older patients were included. Severe infection was seen in 51% (95% CI– 36-65%, I2–95%) patients while 22% (95% CI– 16-28%, I2–88%) were critically ill. Overall, 11% (95% CI– 5-21%, I2–98%) patients died. The common comorbidities were hypertension (48, 95% CI– 36-60% I2–92%), diabetes mellitus (22, 95% CI– 13-32%, I2–86%) and cardiovascular disease (19, 95% CI – 11-28%, I2–85%). Common symptoms were fever (83, 95% CI– 66-97%, I2–91%), cough (60, 95% CI– 50-70%, I2–71%) and dyspnoea (42, 95% CI– 19-67%, I2–94%). Overall, 84% (95% CI– 60-100%, I2–81%) required oxygen support and 21% (95% CI– 0-49%, I2–91%) required mechanical ventilation. Majority of studies had medium to high risk of bias and overall quality of evidence was low for all outcomes. Conclusion Approximately half of older patients with COVID-19 have severe infection, one in five are critically ill and one in ten die. More high-quality evidence is needed to study outcomes in this vulnerable patient population and factors affecting these outcomes.

scholarly journals Presentation, clinical features, and results of intervention in upper extremity fibromuscular dysplasia

2017 ◽  
Vol 66 (2) ◽  
pp. 554-563 ◽  
Author(s):  
Nancy Nguyen ◽  
Aditya Sharma ◽  
Jonathan K. West ◽  
Maya Serhal ◽  
Ellen Brinza ◽  
...  
Keyword(s):  
Upper Extremity ◽  
Clinical Features ◽  
Fibromuscular Dysplasia

scholarly journals Epidemiology and clinical features of COVID-19 outbreaks in aged care facilities: A systematic review and meta-analysis

2021 ◽  
Vol 33 ◽  
pp. 100771 ◽  
Author(s):  
Mohammad Rashidul Hashan ◽  
Nicolas Smoll ◽  
Catherine King ◽  
Hannah Ockenden-Muldoon ◽  
Jacina Walker ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Features ◽  
Meta Analysis ◽  
Aged Care ◽  
Care Facilities ◽  
Aged Care Facilities

scholarly journals Clinical Features of Coexisting Anti-NMDAR and MOG Antibody-Associated Encephalitis: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Jiayue Ding ◽  
Xiangyu Li ◽  
Zhiyan Tian
Keyword(s):  
Optic Neuritis ◽  
Clinical Features ◽  
Antibody Titer ◽  
Fixed Effects ◽  
Clinical Symptoms ◽  
Case Reports ◽  
Involuntary Movement ◽  
Meta Analysis ◽  
Abnormal Behavior ◽  
Fixed Effects Model

Coexisting anti-NMDAR and MOG antibody (anti-NMDAR-IgG+/MOG-IgG+)-associated encephalitis have garnered great attention. This study aimed to perform a secondary analysis to determine the clinical features of this disease. We searched several databases for related publications published prior to April 2021. A pooled analysis was conducted with the fixed-effects model using the Mante-Haenszel method (I2 ≤ 50%), or the random-effects model computed by the DerSimonian–Laird method (I2 > 50%). Stata software (version 15.0 SE) was used for the analyses. Nine observational studies and 16 case reports (58 cases with anti-NMDAR-IgG+/MOG-IgG+, 21.0 [8.5, 29.0] years, male 58.6%) were included. The incidences (95%CI) of anti-NMDAR-IgG+/MOG-IgG+ in the patients with serum MOG-IgG+ and CSF anti-NMDAR-IgG+ were 0.09 (0.02–0.19) and 0.07 (0.01–0.19), respectively. The median [IQR] of CSF anti-NMDAR antibody titer was 32 [10, 100], and the serum anti-MOG antibody titer was 100 [32, 320]. The prominent clinical symptoms were encephalitic manifestations, including seizures (56.9%) and abnormal behavior (51.7%), rather than demyelinating manifestations, such as speech disorder (34.5%) and optic neuritis (27.6%). Relapse occurred in 63.4% of anti-NMDAR-IgG+/MOG-IgG+ patients, in whom 50.0% of cases relapsed with encephalitic manifestations, and 53.8% relapsed with demyelinating manifestations. The common MRI changes were in the cortex or subcortex (70.7%) and brainstem (31.0%). 31.3% of patients presented with unilateral cerebral cortical encephalitis with epilepsy and 12.5% displayed bilateral frontal cerebral cortex encephalitis. Anti-NMDAR-IgG+/MOG-IgG+ patients showed more frequent mental behavior (OR, 95%CI, 68.38, 1.36–3,434.37), involuntary movement (57.86, 2.53–1,325.11), sleep disorders (195.00, 7.07–5,380.15), and leptomeninge lesions (7.32, 1.81–29.58), and less frequent optic neuritis (0.27, 0.09–0.83) compared to anti-NMDAR-IgG−/MOG-IgG+ patients and presented more common relapse (5.63, 1.75–18.09), preceding infection (2.69, 1.03–7.02), subcortical lesions (116.60, 4.89–2,782.09), basal ganglia lesions (68.14, 2.99–1,554.27), brainstem lesions (24.09, 1.01–574.81), and spinal cord lesions (24.09, 1.01–574.81) compared to anti-NMDAR-IgG+/MOG-IgG−. In conclusion, anti-NMDAR-IgG+/MOG-IgG+ was rarely observed, but the incidence rate of relapse was very high. The overall symptoms seemed to be similar to those of NMDAR encephalitis.

scholarly journals Indian scenario of IgA nephropathy: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
pp. 159-65
Author(s):  
Anju Khairwa
Keyword(s):  
Systematic Review ◽  
Iga Nephropathy ◽  
Clinical Features ◽  
Meta Analysis ◽  
Microscopic Hematuria ◽  
Macroscopic Hematuria ◽  
Female Ratio ◽  
Cochrane Database ◽  
Male Female Ratio ◽  
Indian Scenario

Background: IgA nephropathy (IgAN) is most common primary glomerulopathy. There are variations in prevalence of IgAN and its clinical features in different studies from India. Aim: To summarize overall scenario of IgAN in India. Methods: In this systematic review, studies related to IgAN and related renal disease were included. Data searched were PubMed, EMBASE, Google scholar, and Cochrane Database from inception to 31st January 2019. Results: Total 49 studies (N=2480) were included: 21studies (N=2309) of primary IgAN; 19 studies (N=21) of Secondary IgAN; four studies (N=133) of IgA vasculitis nephropathy (IgAVN); and five studies (N=17) of IgA dominant nephropathy (IgADN). Prevalence of IgAN was 16.5% in India. Age of affected persons was ranging from 27.2±16.7 to 48.6±21.3 years . Male female ratio was 1.8:1. Clinical features of Primary IgAN, IgAVN, IgADN & Secondary IgAN were microscopic hematuria (49.6%, 44.4%, 15.6% & 59.5%), macroscopic hematuria (5.1%, 0.4%,40.9%,& 35.7%), Subnephrotic proteinuria (42.1%, 29.4%, 23.2%, & 52.3%), nephrotic proteinuria (16.0%, 4.4%, 76.8%,& 47.6%), and hypertension (25.8%,18.3%, 35.5%,& 47.6%).. The 24 hours proteinuria was ranging from 2.6±1.5 to 4.7±2.3 gm/day and serum creatinine (mg/dl) was ranging from 0.9±0 to 3.5±3.9 mg/dl. Histolomorphologically, all type of IgAN showed mesangial hypercellularity and Immunofluorescence revealed IgA deposition. Conclusion: The overall prevalence of primary IgAN in India was 16.5%. The subnephrotic proteinuria and microscopic hematuria were common clinical features. Keywords: IgA Nephropathy; histomorphology; prevalence; India.

Sign in / Sign up

Export Citation Format

Share Document